Literature DB >> 15958586

Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.

Daniel Zips1, Wolfgang Eicheler, Peter Geyer, Franziska Hessel, Annegret Dörfler, Howard D Thames, Martin Haberey, Michael Baumann.   

Abstract

Previous experiments with PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, using irradiated human FaDu squamous cell carcinoma in nude mice, suggested that radiation-damaged tumor vessels are more sensitive to VEGFR inhibition. To test this hypothesis, the tumor transplantation site (i.e., the right hind leg of nude mice) was irradiated 10 days before transplantation of FaDu to induce radiation damage in the host tissue. FaDu tumors vascularized by radiation-damaged blood vessels appeared later, grew at a slower rate, and showed more necrosis and a smaller vessel area per central tumor section than controls. PTK787/ZK222584 at a daily dose of 50 mg/kg body weight had no impact on growth of control tumors. In contrast, tumors vascularized by radiation-damaged vessels responded to PTK787/ZK222584 with longer latency and slower growth rate than controls, and a trend toward further increase in necrosis, indicating that irradiated tumor vessels are more susceptible to VEGFR inhibition than unirradiated vessels. Although not proving causality, expression analysis of VEGF and VEGFR2 shows that enhanced sensitivity of irradiated vessels to a specific inhibitor of VEGFR tyrosine kinases correlates with increased expression of the molecular target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958586     DOI: 10.1158/0008-5472.CAN-04-3379

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.

Authors:  Iris Eke; Ulrike Koch; Stephanie Hehlgans; Veit Sandfort; Fabio Stanchi; Daniel Zips; Michael Baumann; Anna Shevchenko; Christian Pilarsky; Michael Haase; Gustavo B Baretton; Véronique Calleja; Banafshé Larijani; Reinhard Fässler; Nils Cordes
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

Authors:  J C Becker; C Muller-Tidow; H Serve; W Domschke; T Pohle
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.

Authors:  Randy D'Amico; Liang Lei; Benjamin C Kennedy; Julia Sisti; Victoria Ebiana; Celina Crisman; James G Christensen; Orlando Gil; Steven S Rosenfeld; Peter Canoll; Jeffrey N Bruce
Journal:  Neurol Res       Date:  2012-03-05       Impact factor: 2.448

4.  HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.

Authors:  Nabendu Pore; Anjali K Gupta; George J Cerniglia; Amit Maity
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 5.  Are cancer stem cells radioresistant?

Authors:  Walter N Hittelman; Yong Liao; Li Wang; Luka Milas
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

Review 6.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

Review 7.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Authors:  Pinaki R Dutta; Amit Maity
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

8.  Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis.

Authors:  Sunil Sheth; Wissam Bleibel; Chandrashekhar Thukral; Yousif A-Rahim; Guido Beldi; Eva Csizmadia; Simon C Robson
Journal:  Purinergic Signal       Date:  2009-04-01       Impact factor: 3.765

Review 9.  Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.

Authors:  Chryso Kanthou; Gillian Tozer
Journal:  Br J Radiol       Date:  2018-09-05       Impact factor: 3.039

10.  Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.

Authors:  Colin Brooks; Tommy Sheu; Kathleen Bridges; Kathy Mason; Deborah Kuban; Paul Mathew; Raymond Meyn
Journal:  Radiat Oncol       Date:  2012-09-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.